Newly Approved Agent Also Effective in MDS

]]>(MedPage Today) -- Treatment with luspatercept (Reblozyl) reduced the need for frequent blood transfusions in lower-risk myelodysplastic syndromes (MDS) patients with ring sideroblasts, the phase III MEDALIST trial showed.Among the 229 participants...